Trial 1B-23-4


A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Biological Response Modifier, Immunotherapy
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Daphne Stewart, M.D.
Other Trial Staff:  Marissa Aldana, Coordinator, Mary Ordaz, D.M., Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Niranjan Bhatt, D.M., Apoorva Vishwanath, D.M., Othesia Glasgow, D.M., Maria Kaufman, Coordinator, Kimberly Arieli, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.